Skip to main content
Erschienen in: World Journal of Surgery 7/2023

17.04.2023 | Original Scientific Report

A Novel ypTLM Staging System Based on LODDS for Gastric Cancer After Neoadjuvant Therapy: Multicenter and Large-Sample Retrospective Study

verfasst von: Si-Jin Que, Qing Zhong, Qi-Yue Chen, Mark J. Truty, Su Yan, Yu-Bin Ma, Fang-Hui Ding, Chao-Hui Zheng, Ping Li, Jia-Bin Wang, Jian-Xian Lin, Jun Lu, Long-Long Cao, Mi Lin, Ru-Hong Tu, Ju-Li Lin, Hua-Long Zheng, Chang-Ming Huang

Erschienen in: World Journal of Surgery | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

The accuracy of the eighth AJCC ypTNM staging system on the prognosis of gastric cancer (GC) patients after neoadjuvant therapy (NAT) is controversial. This study aimed to develop and validate a novel staging system using the log odds of positive lymph nodes scheme (LODDS).

Methods

A retrospective analysis of 606 GC patients who underwent radical gastrectomy after neoadjuvant therapy was conducted as the development cohort. (Fujian Medical University Affiliated Union Hospital (n = 183), Qinghai University Affiliated Hospital (n = 169), Mayo Clinic (n = 236), Lanzhou University First Hospital (n = 18)). The validation cohort came from the SEER database (n = 1701). A novel ypTLoddsS (ypTLM) staging system was established using the 3-year overall survival. The predictive performance of two systems was compared.

Results

Two-step multivariate Cox regression analysis in both cohorts showed that ypTLM was an independent predictor of overall survival of GC patients after neoadjuvant therapy (HR: 1.57, 95% CI: 1.30–1.88, p < 0.001). In the development cohort, ypTLM had better discrimination ability than ypTNM (C-index: 0.663 vs 0.633, p < 0.001), better prediction homogeneity (LR: 97.7 vs. 70.9), and better prediction accuracy (BIC: 3067.01 vs 3093.82; NRI: 0.36). In the validation cohort, ypTLM had a better prognostic predictive ability (C-index: 0.614 vs 0.588, p < 0.001; LR: 11,909.05 vs. 11,975.75; BIC: 13,263.71 vs 13,328.24; NRI: 0.22). The time-dependent ROC curve shows that the predictive performance of ypTLM is better than ypTNM, and the analysis of the decision curve shows that ypTLM achieved better net benefits.

Conclusion

A LODDS-based ypTLM staging system based on multicenter data was established and validated. The predictive performance was superior to the eighth AJCC ypTNM staging system.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMedCrossRef Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMedCrossRef
3.
Zurück zum Zitat Amin MB, Greene FL, Edge SB et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99PubMedCrossRef Amin MB, Greene FL, Edge SB et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99PubMedCrossRef
4.
Zurück zum Zitat Yan Y, Yang A, Lu L et al (2021) Impact of neoadjuvant therapy on minimally invasive surgical outcomes in advanced gastric cancer: an international propensity score-matched study. Ann Surg Oncol 28(3):1428–1436PubMedCrossRef Yan Y, Yang A, Lu L et al (2021) Impact of neoadjuvant therapy on minimally invasive surgical outcomes in advanced gastric cancer: an international propensity score-matched study. Ann Surg Oncol 28(3):1428–1436PubMedCrossRef
5.
Zurück zum Zitat Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393(10184):1948–1957PubMedCrossRef Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393(10184):1948–1957PubMedCrossRef
6.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20PubMedCrossRef Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20PubMedCrossRef
7.
Zurück zum Zitat Macdonald JS, Smalley SR, Benedetti J et al (2021) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730CrossRef Macdonald JS, Smalley SR, Benedetti J et al (2021) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730CrossRef
8.
Zurück zum Zitat Zhong Q, Chen QY, Parisi A et al (2021) Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: a multi-institutional study. Oncologist 26(1):e99–e110PubMedCrossRef Zhong Q, Chen QY, Parisi A et al (2021) Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: a multi-institutional study. Oncologist 26(1):e99–e110PubMedCrossRef
9.
Zurück zum Zitat Lin JX, Yoon C, Desiderio J et al (2019) Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy. Br J Surg 106(9):1187–1196PubMedCrossRef Lin JX, Yoon C, Desiderio J et al (2019) Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy. Br J Surg 106(9):1187–1196PubMedCrossRef
10.
Zurück zum Zitat Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108PubMedCrossRef Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108PubMedCrossRef
11.
Zurück zum Zitat Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27(6):851–856PubMedCrossRef Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27(6):851–856PubMedCrossRef
12.
Zurück zum Zitat Ott K, Sendler A, Becker K et al (2003) Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6(3):159–167PubMedCrossRef Ott K, Sendler A, Becker K et al (2003) Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6(3):159–167PubMedCrossRef
13.
Zurück zum Zitat Shen L, Shan YS, Hu HM et al (2013) Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 14(12):e535–e547PubMedCrossRef Shen L, Shan YS, Hu HM et al (2013) Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 14(12):e535–e547PubMedCrossRef
14.
Zurück zum Zitat In H, Ravetch E, Langdon-Embry M et al (2018) The newly proposed clinical and post-neoadjuvant therapy staging classifications for gastric adenocarcinoma for the American joint committee on cancer (AJCC) staging. Gastric Cancer 21(1):1–9PubMedCrossRef In H, Ravetch E, Langdon-Embry M et al (2018) The newly proposed clinical and post-neoadjuvant therapy staging classifications for gastric adenocarcinoma for the American joint committee on cancer (AJCC) staging. Gastric Cancer 21(1):1–9PubMedCrossRef
15.
Zurück zum Zitat Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations Cancer 73(11):2680–2686PubMed Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations Cancer 73(11):2680–2686PubMed
16.
Zurück zum Zitat Lee CW, Wilkinson KH, Sheka AC et al (2016) The log odds of positive lymph nodes stratifies and predicts survival of high-risk individuals among stage iii rectal cancer patients. Oncologist 21(4):425–432PubMedPubMedCentralCrossRef Lee CW, Wilkinson KH, Sheka AC et al (2016) The log odds of positive lymph nodes stratifies and predicts survival of high-risk individuals among stage iii rectal cancer patients. Oncologist 21(4):425–432PubMedPubMedCentralCrossRef
17.
18.
Zurück zum Zitat Yu Y, Zhang P, Yao R et al (2020) Prognostic value of log odds of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery: a SEER population-based study. Transl Lung Cancer Res 9(4):1285–1301PubMedPubMedCentralCrossRef Yu Y, Zhang P, Yao R et al (2020) Prognostic value of log odds of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery: a SEER population-based study. Transl Lung Cancer Res 9(4):1285–1301PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Sun Z, Xu Y, de Li M et al (2010) Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection. Cancer 116(11):2571–2580PubMedCrossRef Sun Z, Xu Y, de Li M et al (2010) Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection. Cancer 116(11):2571–2580PubMedCrossRef
20.
Zurück zum Zitat Zhang JX, Song W, Chen ZH et al (2013) Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol 14(13):1295–1306PubMedCrossRef Zhang JX, Song W, Chen ZH et al (2013) Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol 14(13):1295–1306PubMedCrossRef
21.
Zurück zum Zitat Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252–7259PubMedCrossRef Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252–7259PubMedCrossRef
22.
Zurück zum Zitat Sun Z, Zhu GL, Lu C et al (2009) A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion: superficial muscularis propria versus deep muscularis propria/subserosa. Ann Surg 249(5):768–775PubMedCrossRef Sun Z, Zhu GL, Lu C et al (2009) A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion: superficial muscularis propria versus deep muscularis propria/subserosa. Ann Surg 249(5):768–775PubMedCrossRef
23.
Zurück zum Zitat Harrell FE, Califf RM, Pryor DB, Rosati RA et al (1982) Evaluating the yield of medical tests. JAMA 247(18):2543–2546PubMedCrossRef Harrell FE, Califf RM, Pryor DB, Rosati RA et al (1982) Evaluating the yield of medical tests. JAMA 247(18):2543–2546PubMedCrossRef
24.
Zurück zum Zitat Wang W, Sun Z, Deng JY et al (2018) A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer. Cancer Commun 38(1):23CrossRef Wang W, Sun Z, Deng JY et al (2018) A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer. Cancer Commun 38(1):23CrossRef
25.
Zurück zum Zitat Wang J, Dang P, Raut CP et al (2012) Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database. Ann Surg 255(3):478–485PubMedCrossRef Wang J, Dang P, Raut CP et al (2012) Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database. Ann Surg 255(3):478–485PubMedCrossRef
27.
Zurück zum Zitat Edeline J, Blanc JF, Johnson P et al (2016) A multicentre comparison between child pugh and albumin-bilirubin scores in patients treated with sorafenib for hepatocellular carcinoma. Liver Int 36(12):1821–1828PubMedCrossRef Edeline J, Blanc JF, Johnson P et al (2016) A multicentre comparison between child pugh and albumin-bilirubin scores in patients treated with sorafenib for hepatocellular carcinoma. Liver Int 36(12):1821–1828PubMedCrossRef
28.
Zurück zum Zitat Assmus B, Cremer S, Kirschbaum K et al (2021) Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur Heart J 42(3):257–265PubMedCrossRef Assmus B, Cremer S, Kirschbaum K et al (2021) Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur Heart J 42(3):257–265PubMedCrossRef
29.
Zurück zum Zitat Kerr KF, Brown MD, Zhu K et al (2016) Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol 34(21):2534–2540PubMedPubMedCentralCrossRef Kerr KF, Brown MD, Zhu K et al (2016) Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol 34(21):2534–2540PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Zhu D, Chung HF, Pandeya N et al (2018) Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: a pooled analysis of individual data from 17 observational studies. PLoS Med 15(11):e1002704PubMedPubMedCentralCrossRef Zhu D, Chung HF, Pandeya N et al (2018) Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: a pooled analysis of individual data from 17 observational studies. PLoS Med 15(11):e1002704PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Leening MJ, Vedder MM, Witteman JC et al (2014) Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician’s guide. Ann Intern Med 160(2):122–131PubMedCrossRef Leening MJ, Vedder MM, Witteman JC et al (2014) Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician’s guide. Ann Intern Med 160(2):122–131PubMedCrossRef
32.
Zurück zum Zitat Poretsky E, Huffaker A (2020) MutRank: an R shiny web-application for exploratory targeted mutual rank-based coexpression analyses integrated with user provided supporting information. PeerJ 8:e10264PubMedPubMedCentralCrossRef Poretsky E, Huffaker A (2020) MutRank: an R shiny web-application for exploratory targeted mutual rank-based coexpression analyses integrated with user provided supporting information. PeerJ 8:e10264PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Lowy AM, Mansfield PF, Leach SD et al (1999) Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229(3):303–308PubMedPubMedCentralCrossRef Lowy AM, Mansfield PF, Leach SD et al (1999) Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229(3):303–308PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Wang FH, Zhang XT, Li YF et al (2021) The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun 41(8):747–795CrossRef Wang FH, Zhang XT, Li YF et al (2021) The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun 41(8):747–795CrossRef
35.
Zurück zum Zitat Sah BK, Zhang B, Zhang H et al (2020) Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun 11(1):6093PubMedPubMedCentralCrossRef Sah BK, Zhang B, Zhang H et al (2020) Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun 11(1):6093PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Li Z, Shan F, Ying X et al (2019) Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial. JAMA Surg 154(12):1093–1101PubMedPubMedCentralCrossRef Li Z, Shan F, Ying X et al (2019) Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial. JAMA Surg 154(12):1093–1101PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Chen X, Liu H, Li G et al (2019) Implications of clinical research on adjuvant chemotherapy for gastric cancer: where to go next? Chin J Cancer Res 31(6):892–900PubMedPubMedCentralCrossRef Chen X, Liu H, Li G et al (2019) Implications of clinical research on adjuvant chemotherapy for gastric cancer: where to go next? Chin J Cancer Res 31(6):892–900PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Wang X, Wan F, Pan J et al (2009) Prognostic value of the ratio of metastatic lymph nodes in gastric cancer: an analysis based on a Chinese population. J Surg Oncol 99(6):329–334PubMedCrossRef Wang X, Wan F, Pan J et al (2009) Prognostic value of the ratio of metastatic lymph nodes in gastric cancer: an analysis based on a Chinese population. J Surg Oncol 99(6):329–334PubMedCrossRef
Metadaten
Titel
A Novel ypTLM Staging System Based on LODDS for Gastric Cancer After Neoadjuvant Therapy: Multicenter and Large-Sample Retrospective Study
verfasst von
Si-Jin Que
Qing Zhong
Qi-Yue Chen
Mark J. Truty
Su Yan
Yu-Bin Ma
Fang-Hui Ding
Chao-Hui Zheng
Ping Li
Jia-Bin Wang
Jian-Xian Lin
Jun Lu
Long-Long Cao
Mi Lin
Ru-Hong Tu
Ju-Li Lin
Hua-Long Zheng
Chang-Ming Huang
Publikationsdatum
17.04.2023
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 7/2023
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-023-06994-7

Weitere Artikel der Ausgabe 7/2023

World Journal of Surgery 7/2023 Zur Ausgabe

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.